Cipla Reports 15.2% PAT Growth in Q2 FY25

30 Oct 2024 , 12:02 PM

Cipla, India’s third-largest pharmaceutical company, reported a 15.2% year-on-year growth in its consolidated profit after tax (PAT) for the second quarter of FY25, reaching ₹1,303 Crore, compared to ₹1,131 Crore during the same period in FY24. This significant increase reflects the company’s strong financial health and operational efficiencies.

The company’s revenue from product sales during the quarter grew by 5.6%, totaling ₹6,961 Crore, up from ₹6,589 Crore in Q2 FY24. The growth in revenue can be attributed to a robust performance in the domestic market, an improved product mix, and enhanced operational efficiencies that positively impacted overall profitability.

Sequentially, Cipla’s revenue from operations saw an increase of 5.1%, while PAT experienced a 10.6% growth compared to the previous quarter. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 10.7% year-on-year, reaching ₹2,076 Crore.

In the Indian branded prescription market, Cipla experienced a growth rate of 5%, while its consumer health division recorded an impressive 21% year-on-year growth, supported by leading brands such as Nicotex, Omnigel, and Cipladine.

Cipla’s total research and development expenditure for the quarter reached ₹385 Crore, representing 5.5% of total sales and reflecting a 2% increase year-on-year. This commitment to R&D underscores the company’s focus on innovation and development in the pharmaceutical sector.